As the final big conference of the year, ASH is always something a harbinger of things to come. This year was no exception with plenty to keep pharma-watchers pondering over the festive period. We saw data suggesting that sickle cell patients could soon see an approved gene therapy in what is an increasingly crowded market.  

Battlegrounds for Car-T therapies, menin inhibitors and bispecifics all saw action, with the share prices of the main contenders punished or rewarded accordingly. As ever, ASH has set the deal-making stage for JP Morgan in January – good news for the investors who’ve been looking for something to be confident about for most of the year.